Finally, DeWilde explored future developments in anti-VEGF treatment, including biosimilars, implantable devices like Susvimo, and potential new delivery methods such as eye drops. He emphasized ...

Overall survival was significantly improved in patients treated with brentuximab vedotin plus lenalidomide/rituximab compared with placebo plus lenalidomide/rituximab ...

Roivant, the source of Roche’s TL1A prospect, reported a 21% delta compared to placebo after 12 weeks. Prometheus Biosciences, which Merck acquired, saw a 31% placebo-adjusted rate of endoscopic ...

Roche has put forward a new approach to genetic analysis, which it describes as sequencing-by-expansion—a proprietary method that pulls apart the DNA molecule and amplifies the signal of each ...

But those days had settled down. Or so we thought. This week, Roche made it feel like 2022 again. Just days before the AGBT meeting kicks off in Marco Island, FL, the company hosted a much ...

Roche’s innovative sequencing by expansion (SBX) technology represents a leap forward in next-generation sequencing (NGS), which is playing a vital role in decoding complex diseases like cancer, ...

Planning ahead is the best medicine for a quick and healthy recovery from surgery. Learn about the causes and best treatment options for hair loss. Learn the presurgery tips that can help improve ...

After Novartis and Roche grew their sales last year, the Swiss pharma giants are handing their CEOs larger compensation packages for 2024. At Novartis, CEO Vas Narasimhan’s overall 2024 pay ...

Susvimo was nonferior to intravitreal ranibizumab based on the change from baseline in distance best corrected visual acuity score. The Food and Drug Administration (FDA) has approved Susvimo ...

Public Service Commissioner Sir Brian Roche fears the sheer number of entities, departments and agencies – some of which are small – creates inefficiencies and duplication.